The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its...
Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
At the SABCS 2025 View From the Trenches session, experts discussed how new clinical trial results might transform breast...
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent...
Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.
Researchers are exploring innovative early cancer detection strategies involving tiny cancer hunters, the voice, electronic noses, and more.